XAIR Shares Soar 86% on Heavy Volume as LungFit PH Expands Globally

Introduction

BEYOND AIR INC (ticker: XAIR) is a clinical-stage medical device and biopharmaceutical company headquartered in Garden City, New York. Founded in 2011 as AIT Therapeutics and rebranded on June 26, 2019, the company develops on-demand nitric oxide (NO) delivery systems under the LungFit® product family. These systems utilize patented Ionizer™ and Plasma Pulse Technology™ to generate inhaled NO from ambient air, removing the need for cylinders or cassettes in respiratory care.

Corporate Structure

BEYOND AIR INC employs between 11 and 50 professionals with expertise in biotechnology, clinical research, and medical device manufacturing. The management team is led by Steve Lisi, Chief Executive Officer and Chairman of the Board. Other board members include Erick Lucera, Yoori Lee, Bill Forbes, PharmD, Robert F. Carey, and Robert Goodman. The company’s advisory and support functions encompass clinical training, technical service, and global distribution coordination.

LungFit by Marek Piwnicki

Developments and News

• Stock Performance (September 8, 2025): Shares closed at $4.1150 on the NASDAQ, reflecting an 86.20% increase for the trading day, with 35,865,773 shares traded.
• FDA Approval: The LungFit PH system is FDA-approved for improving oxygenation and reducing the need for extracorporeal membrane oxygenation in term and near-term neonates with hypoxic respiratory failure.
• Global Distribution: As of mid-2025, distribution agreements extend to 34 countries, providing potential access to 2.7 billion people. Partnerships include Valley Children’s Hospital and other pediatric and neonatal care centers.
• Investigational Devices: LungFit®PRO and LungFit®GO are classified as investigational devices under United States federal law, with ongoing clinical evaluations to support future regulatory submissions.

Financial and Strategic Analysis

The trading volume of over 35 million shares on September 8 indicates increased market interest. As a clinical-stage company, BEYOND AIR INC is not yet generating substantial product revenue but its strategy includes:

• Patent-protected technologies that aim to simplify supply chains and reduce storage costs by removing cylinders and cassettes
• Service contracts that encompass devices, accessories, and 24/7 customer support
• Investments in clinical trials and regulatory filings for investigational devices

These strategic components seek to position the company for the adoption of LungFit systems in hospital settings and the potential for revenue growth following regulatory approvals.

Market Position and Industry Context

BEYOND AIR INC operates in the inhaled nitric oxide therapy segment of medical equipment manufacturing. Traditional systems typically depend on prefilled gas cylinders, whereas LungFit systems generate NO on-site from room air, aligning with healthcare trends toward sustainability and cost efficiency. The company’s emphasis on neonatal hypoxic respiratory failure, in addition to planned expansions into adult pulmonary indications, enables it to engage with established suppliers while aiming for operational efficiencies and environmental safety improvements.

TL;DR

• On September 8, 2025, XAIR shares increased 86.20% to $4.1150 with significant trading (35.9 million shares).
• FDA-approved LungFit PH system deployment continues to expand globally through agreements in 34 countries.
• Clinical evaluations of LungFit®PRO and LungFit®GO are underway, with future regulatory submissions anticipated.
• The outlook focuses on scaling hospital adoption, expanding indications beyond neonatal care, and generating revenue through service-based contracts.